FREIENBACH, Switzerland--(BUSINESS WIRE)--EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Bronchitol® (inhaled mannitol) for the treatment of cystic fibrosis (CF) in adults and in children aged 6 years and above as add‐on to other medicines.
Bronchitol® is a precision spray‐dried form of mannitol which is delivered to the lungs by a specially designed, portable inhaler. Bronchitol® improves lung function and helps to clear mucus from the lungs in patients suffering from cystic fibrosis. Patients are required to pass a tolerance test prior to being prescribed Bronchitol® to ensure that they are not hyperresponsive to mannitol.
Bronchitol® is currently marketed in Europe, Russia, Australia and the United States and was developed by Pharmaxis Ltd, a listed pharmaceutical research company in Australia. The clinical program supporting the registration of Bronchitol® consisted of three large-scale global clinical trials and enrolled a total of 1,065 subjects. Bronchitol® use led to a sustained improvement in FEV1 (Forced Expiratory Volume) versus control. The statistically significant improvement in FEV1 was observed over the 26-week treatment period in those patients receiving Bronchitol® when compared to patients in the control group. The most common (≥1/100, <1/10) adverse reactions include cough, hemoptysis, oropharyngeal pain, vomiting, wheezing and headache.
“We’re excited to have achieved this important milestone and that patients living with cystic fibrosis will be able to benefit from this treatment in Switzerland. Bronchitol® offers a portable and discreet option for CF management, with no routine cleaning or maintenance of the inhaler device required,” said Lorraine Zakin, Senior Director Medical Affairs at EffRx Pharmaceuticals.
Cystic fibrosis (CF) is an inherited, life-limiting disease that affects the body’s exocrine glands, which produce mucus, saliva, sweat and tears. In the lungs of a CF patient, the thick mucus and the thinning of the airway surface liquid make it nearly impossible for the cilia to clear bacteria from the airway. According to the Swiss Society for Cystic Fibrosis (CFCH), around 320,000 Swiss people are carriers of an altered gene that can cause CF (approximately one in 25 people)1.
EffRx expects the availability of Bronchitol® in Switzerland in the second half of 2022.
About EffRx Pharmaceuticals
EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.
EffRx pro-actively seeks in-licensing opportunities for Switzerland and Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx had received an orphan drug designation (ODD) from the FDA.
Pharmaxis Ltd is an Australian pharmaceutical research company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing revenue. Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia.